Predicting the Crohnʼs disease activity index from the harvey-bradshaw index

Best, William R.

doi:10.1097/01.mib.0000215091.77492.2a

Cited by 231 publications

(135 citation statements)

References 8 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…Some studies suggest that low 25(OH)D is associated with more active disease, whereas others do not support this premise, based on studies collectively comprising approximately 800 CD participants (Table 1). Understanding this association is complicated by the different parameters applied by studies to capture disease activity, which typically include: (a) clinical activity scores, namely the Crohn's disease activity index (CDAI), currently the gold standard (39) or the HarveyBradshaw index; (40) (b) C-reactive protein (CRP) as a marker of systemic inflammation; (c) faecal calprotectin (41) as a marker of intestinal inflammation. For systemic inflammation, as determined by CRP, current studies broadly agree and show a lack of association with 25(OH)D levels.…”

Section: Vitamin D Status and Associations With Disease Severity In Cmentioning

confidence: 99%

Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn?

O’Sullivan

2014

Proc. Nutr. Soc.

View full text Add to dashboard Cite

There is increasing scientific interest in the field of vitamin D research, moving the focus beyond bone health to other disease processes. Low circulating vitamin D levels have been reported as a risk factor for several pathophysiologically divergent diseases, including cancers, diabetes, CVD, multiple sclerosis and inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease (IBD). But, therein, remains the challenge: can any single nutrient contribute to multiple complex disease mechanisms and, ultimately, have therapeutic potential? The aim of this review is to critically evaluate several strands of scientific evidence surrounding vitamin D and inflammation, primarily focusing on IBD. Epidemiological studies suggest an increased incidence of IBD and rheumatoid arthritis in countries of more northern latitudes, mirroring sunlight patterns. A considerable body of evidence supports the anti-inflammatory effects of vitamin D, at least in animal models of IBD. Although it is accepted that suboptimal vitamin D status is common in IBD, some studies suggest that this associates with more severe disease. With regard to treatment, the data are only beginning to emerge from randomised controlled trials to suggest that people with IBD may remain in remission longer when treated with oral vitamin D. In conclusion, several strands of evidence suggest that vitamin D may modify the immune response in IBD. There is a continued need for large well-designed clinical trials and mechanistic studies to determine if, and how, this emerging promise translates into tangible clinical benefits for people with chronic debilitating diseases such as IBD.

show abstract

Section: Vitamin D Status and Associations With Disease Severity In Cmentioning

confidence: 99%

Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn?

O’Sullivan

2014

Proc. Nutr. Soc.

View full text Add to dashboard Cite

show abstract

“…UC patients were assessed by using Mayo score for assessing ulcerative colitis activity and CD patients with Crohn's Disease Activity Index (13,14). Those who were found to be remitters were enrolled.…”

Section: Patientsmentioning

confidence: 99%

Evaluation of increased subclinical atherosclerosis risk with carotid intima-media thickness and pulse wave velocity in inflamatory bowel disease

Alkan

Karakaş²,

Yıldırım³

2015

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: A significant increase in accelerated atherosclerosis risk have determined in chronic inflammatory diseases. Recent studies have suggested a pathophysiological link between inflamatory bowel disease (IBD) and atherosclerosis; for which carotid intima-media thickness (CIMT) and pulse wave velocity (PWV) has been considered as an early marker. The aim of this study was to determine the presence of early atherosclerosis in IBD patients without clinically diagnosed cardiovascular disease and any coincident risk factors for atherosclerosis. Materials and Methods: 40 IBD patients who are in remission and without known atherosclerosis and also without any risk factors for atherosclerosis (17 Crohn's disease and 23 ulcerative colitis ) and 40 healthy subjects for control group involved in the study. The measurement of bilateral CIMT and carotis-femoral PWV have done in patients and control groups. Results: Significant differences existed between control subjects and patients with IBD in the values of PWV (5.97±0.54 vs. 7.17±0.92 m/sn; p<0.001), maximum CIMT (0.76±0.06 vs. 0.86±0.11mm; p<0.001) and mean CIMT (0.66±0.06 vs 0.74±0.09 mm; p<0.001). In the correlation analysis, a positive correlation has determined between PWV and maximum CIMT and mean CIMT ( p<0.001, r=0.75 / p<0.001, r=0.74 respectively ). Conclusion: IBD patients have an increased risk of subclinical atherosclerosis than healty controls as showed by greater values of CIMT and PWV.

show abstract

“…Informed consent was obtained from all patients, and the protocol was approved by the Human Studies Committee of the IKEM. Each patient had a confirmed diagnosis by standard endoscopic and histological criteria, and disease activity was graded according to the Harvey-Bradshaw index (HBI) or Mayo score (Best 2006). Control samples were taken from patients who underwent colonoscopy because of colon cancer screening examination or polypectomy; all had normal endoscopic findings without macroscopic and microscopic evidence of inflammatory or neoplastic disease.…”

Section: Patients and Tissue Samplesmentioning

confidence: 99%

Expression of Toll-like Receptor 2 (TLR2), TLR4, and CD14 in Biopsy Samples of Patients With Inflammatory Bowel Diseases: Upregulated Expression of TLR2 in Terminal Ileum of Patients With Ulcerative Colitis

Frolova

Drastich

Rossmann

et al. 2007

J Histochem Cytochem.

136

View full text Add to dashboard Cite

Dysregulation of innate and adaptive intestinal immune responses to bacterial microbiota is supposed to be involved in pathogenetic mechanisms of inflammatory bowel diseases (IBDs). We investigated expression of Toll-like receptor 2 (TLR2), TLR4, and their transmembrane coreceptor CD14 inbiopsy samples from patients with IBD and in non-inflamed gut mucosa from controls. Small intestine and colon samples were obtained by colonoscopy from patients with Crohn's disease (CD), ulcerative colitis (UC), and controls. Immunohistochemical analysis of cryostat sections using polyclonal and monoclonal antibodies specific for TLR2, TLR4, and CD14 showed a significant increase in TLR2 expression in the terminal ileum of patients with inactive and active UC against controls. Significant upregulation of TLR4 expression relative to controls was found in the terminal ileum and rectum of UC patients in remission and in the terminal ileum of CD patients with active disease. CD14 expression was upregulated in the terminal ileum of CD patients in remission and with active disease, in the cecum of UC patients in remission and with active disease, and in rectum of UC patients with active disease. Hence, dysregulation of TLR2, TLR4, and CD14 expression in different parts of the intestinal mucosa may be crucial in IBD pathogenesis.

show abstract

Predicting the Crohnʼs disease activity index from the harvey-bradshaw index

Abstract: There is a good but far from perfect relationship between CDAI and HBI. CDAI is preferred for clinical trials; HBI is easier to use.

Cited by 231 publications

References 8 publications

Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn?

Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn?

Evaluation of increased subclinical atherosclerosis risk with carotid intima-media thickness and pulse wave velocity in inflamatory bowel disease

Expression of Toll-like Receptor 2 (TLR2), TLR4, and CD14 in Biopsy Samples of Patients With Inflammatory Bowel Diseases: Upregulated Expression of TLR2 in Terminal Ileum of Patients With Ulcerative Colitis

Contact Info

Product

Resources

About